Drugs / Modified FOLFIRINOX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06360354 Background | May 2024 → Oct 2026 expected | digestive system carcinoma | Amgen | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modified FOLFIRINOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360354 ↗ |
| Route | Intravenous | “Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV” NCT06360354 ↗ |